
Opinion|Videos|November 25, 2024
Current Landscape of Bispecific Therapies for RRMM
Key Takeaways
- Bispecific therapies target both tumor antigens and T-cell receptors, enhancing immune responses against myeloma cells in RRMM.
- Several bispecific antibodies are approved or in clinical trials, showing promise in overcoming resistance to conventional therapies.
Panelists discuss how bispecific T-cell–engaging therapies targeting BCMA, GPRC5D, and FcRH5 have emerged as novel immunotherapeutic approaches showing meaningful clinical activity for patients with heavily pretreated relapsed/refractory multiple
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following
- Provide a brief overview of the bispecific therapies currently available for the treatment of relapsed/refractory multiple myeloma (RRMM).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Brain Imaging Study Links Long COVID to Dopamine Neuron Injury, Pointing to Repurposed Treatments
2
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
3
How AON Supports Safe Outpatient Bispecific Therapy in Community Oncology
4
Chronic Low Back Pain Treatments Must Be Weighed Against Risk, Cost, and Limited Benefit
5






































































































